Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2016
Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian CancerLaura Mansi, Martin Demarchi, Fernando Bazan, et al.
Bulletin Du Cancer|October 17, 2019
[Adjuvant hormonal therapy for early breast cancer: Assessment of patients' satisfaction]Julie Vardanega, Julie Henriques, Charlotte Pourcelot, et al.
Anti-Cancer Drugs|September 16, 2005
Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein bindingBernard Royer, Emmanuel Guardiola, Emmanuel Polycarpe, et al.
Rare Tumors|November 9, 2011
Efficacy of trabectedin in metastatic solitary fibrous tumorLoïc Chaigneau, Elsa Kalbacher, Antoine Thiery-Vuillemin, et al.
Bulletin Du Cancer|May 30, 2015
[Efficacy, safety and cost of eribulin in patients with metastatic breast cancer]Marie-Justine Paillard, Elsa Curtit, Erion Dobi, et al.
Breast Cancer Research and Treatment|January 25, 2018
Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherenceCharlotte Pourcelot, Emeline Orillard, Gilles Nallet, et al.
Bulletin Du Cancer|August 6, 2014
[Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region]Virginie Nerich, Elsa Curtit, Fernando Bazan, et al.
Frontiers in Cardiovascular Medicine|October 10, 2022
Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumabQuentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, et al.
BMC Cancer|May 17, 2023
A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN studyChloé Drozd, Elsa Curtit, Quentin Jacquinot, et al.
Clinical Breast Cancer|July 7, 2024
Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast CancerAntoine El Kaddissi, Dewi Vernerey, Antoine Falcoz, et al.
Pageof 5